Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

[39] Insulin secretion is typically associated with release of islet amyloid polypeptide (IAPP), also known as amylin, which has been hypothesized to predict the degree of β-cell dysfunction.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...

GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...

Amylin is produced in the pancreatic beta cells and co-secreted ... Forward looking statements This press release contains “forward-looking statements”, as that term is defined in the Private ...

The candidate is a long-acting amylin analog for the treatment of obesity, and I am delighted to see that AbbVie did not just in-license another incretin therapy (GLP-1 or GLP-1/GIP agonist ...

Amylin, a satiety hormone, has been identified as a potential ... Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of ...

Amylin, a satiety hormone ... Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities ...